A multi-center, randomized, double-blind, active-control, 96 week, phase III trial of the efficacy and safety of clevudine compared with adefovir at weeks 48 and 96 in nucleoside treatment-naive patients with HBeAg negative chronic hepatitis due to hepatitis B virus
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Clevudine (Primary) ; Adefovir
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Acronyms QUASH-2
- Sponsors Pharmasset
- 08 Apr 2022 This trial has been completed in Spain (End Date: 31 May 2009), according to European Clinical Trials Database record.
- 20 Apr 2009 Status changed from recruiting to discontinued, according to Pharmasset media release.
- 08 Jul 2008 Pharmasset plans to submit the 48-week data from this study to the FDA as a basis for clevudine marketing approval.